AU2022345084A1 - Triple-agent therapy for cancer treatment - Google Patents
Triple-agent therapy for cancer treatment Download PDFInfo
- Publication number
- AU2022345084A1 AU2022345084A1 AU2022345084A AU2022345084A AU2022345084A1 AU 2022345084 A1 AU2022345084 A1 AU 2022345084A1 AU 2022345084 A AU2022345084 A AU 2022345084A AU 2022345084 A AU2022345084 A AU 2022345084A AU 2022345084 A1 AU2022345084 A1 AU 2022345084A1
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- gefitinib
- tamoxifen
- regimen
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163244412P | 2021-09-15 | 2021-09-15 | |
| US63/244,412 | 2021-09-15 | ||
| PCT/US2022/043601 WO2023043883A1 (en) | 2021-09-15 | 2022-09-15 | Triple-agent therapy for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022345084A1 true AU2022345084A1 (en) | 2024-03-28 |
Family
ID=85603487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022345084A Pending AU2022345084A1 (en) | 2021-09-15 | 2022-09-15 | Triple-agent therapy for cancer treatment |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12611411B2 (https=) |
| EP (1) | EP4401720A4 (https=) |
| JP (1) | JP2024531765A (https=) |
| KR (1) | KR20240060625A (https=) |
| CN (1) | CN118159262A (https=) |
| AU (1) | AU2022345084A1 (https=) |
| CA (1) | CA3231639A1 (https=) |
| IL (1) | IL311229A (https=) |
| MX (1) | MX2024003333A (https=) |
| WO (1) | WO2023043883A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2644194T3 (en) * | 2008-03-18 | 2017-07-03 | Genentech Inc | Combinations of an anti-HER2 antibody-drug conjugate and docetaxel |
| US20100189683A1 (en) | 2008-11-14 | 2010-07-29 | Ascenta Therapeutics, Inc. | Pulsatile Dosing of Gossypol for Treatment of Disease |
| KR101874390B1 (ko) * | 2013-09-26 | 2018-07-04 | 파이브3 제노믹스, 엘엘씨 | 바이러스-연관 종양을 위한 시스템, 방법, 및 조성물 |
-
2022
- 2022-09-15 MX MX2024003333A patent/MX2024003333A/es unknown
- 2022-09-15 US US18/689,980 patent/US12611411B2/en active Active
- 2022-09-15 WO PCT/US2022/043601 patent/WO2023043883A1/en not_active Ceased
- 2022-09-15 EP EP22870665.1A patent/EP4401720A4/en active Pending
- 2022-09-15 CN CN202280069063.5A patent/CN118159262A/zh active Pending
- 2022-09-15 IL IL311229A patent/IL311229A/en unknown
- 2022-09-15 KR KR1020247010862A patent/KR20240060625A/ko active Pending
- 2022-09-15 JP JP2024516808A patent/JP2024531765A/ja active Pending
- 2022-09-15 CA CA3231639A patent/CA3231639A1/en active Pending
- 2022-09-15 AU AU2022345084A patent/AU2022345084A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024531765A (ja) | 2024-08-29 |
| CA3231639A1 (en) | 2023-03-23 |
| EP4401720A4 (en) | 2025-07-30 |
| CN118159262A (zh) | 2024-06-07 |
| IL311229A (en) | 2024-05-01 |
| MX2024003333A (es) | 2024-05-20 |
| US20250127791A1 (en) | 2025-04-24 |
| WO2023043883A1 (en) | 2023-03-23 |
| US12611411B2 (en) | 2026-04-28 |
| EP4401720A1 (en) | 2024-07-24 |
| KR20240060625A (ko) | 2024-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Morabito et al. | Treatment of small cell lung cancer | |
| Safran et al. | Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity | |
| TWI630924B (zh) | 使用包含微脂體伊立替康（ｉｒｉｎｏｔｅｃａｎ）的組合療法治療胰臟癌的方法 | |
| WO2021098679A1 (zh) | Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途 | |
| RU2662298C2 (ru) | Лечение рака комбинацией плинабулина и таксана | |
| US12102613B2 (en) | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms | |
| US20110243933A1 (en) | Perifosine and Capecitabine as a Combined Treatment for Cancer | |
| US12213958B2 (en) | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms | |
| BR112017028287A2 (en) | COMBINATION OF THE HDAC INHIBITOR AND ANTICORPIDE ANTI-PD- L1 FOR CANCER TREATMENT | |
| CN108025013A (zh) | 用于治疗骨髓瘤的赛度替尼 | |
| KR20140040728A (ko) | Pi3k 억제제 화합물을 사용한 중피종 치료 방법 | |
| Kelley et al. | Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206 | |
| EP3691632B1 (en) | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms | |
| US20260053791A1 (en) | Use of tivozanib to treat subjects with refractory cancer | |
| CN108135892A (zh) | 用于治疗癌症的mdm2抑制剂的给药方案 | |
| JP2018531273A6 (ja) | がんを治療するためのｍｄｍ２阻害剤の投与計画 | |
| Anampa et al. | Phase I trial of veliparib, a poly ADP ribose polymerase inhibitor, plus metronomic cyclophosphamide in metastatic HER2-negative breast cancer | |
| Stathopoulos et al. | Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects | |
| TWI726133B (zh) | 基於癌細胞之代謝特異性之新穎抗惡性腫瘤劑 | |
| US12611411B2 (en) | Triple-agent therapy for cancer treatment | |
| WO2021175432A1 (en) | Method for administration of an anti cancer agent | |
| Wiśniowski | Efficacy of trifluridine/tipiracil as IV line chemotherapy in a young woman with metastatic colorectal cancer. A case report | |
| JP2009509974A (ja) | 抗癌治療 | |
| WO2025059579A1 (en) | Methods of treating mat2a related diseases | |
| CN105228611B (zh) | 用于治疗或预防头颈癌的pi3激酶抑制剂与紫杉醇的组合 |